Hsieh Dar-jen, CEO of ACRO Biomedical, sees strong demand in mainland China for cornea transplants. Photo: Nora Tam Hsieh Dar-jen, CEO of ACRO Biomedical, sees strong demand in mainland China for cornea transplants. Photo: Nora Tam
Hsieh Dar-jen, CEO of ACRO Biomedical, sees strong demand in mainland China for cornea transplants. Photo: Nora Tam
Health in China

Taiwan biotech firm eyes Hong Kong IPO for push into mainland China market for cornea transplants

ACRO Biomedical plans a reverse takeover to place its assets into a Hong Kong holding company

Topic |   Health in China
Hsieh Dar-jen, CEO of ACRO Biomedical, sees strong demand in mainland China for cornea transplants. Photo: Nora Tam Hsieh Dar-jen, CEO of ACRO Biomedical, sees strong demand in mainland China for cornea transplants. Photo: Nora Tam
Hsieh Dar-jen, CEO of ACRO Biomedical, sees strong demand in mainland China for cornea transplants. Photo: Nora Tam
READ FULL ARTICLE